Correspondence 0001213900-25-126780 from Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc.
Date: Dec. 30, 2025 · CIK: 0001937993 · Accession: 0001213900-25-126780
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292444
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Tim Buchmiller Re: Cadrenal Therapeutics, Inc. Registration Statement on Form S-1 Filed December 29, 2025 File No: 333-292444
Dear Mr. Buchmiller:
Cadrenal Therapeutics, Inc. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-292444), be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Wednesday, December 31, 2025 , at 4:00 p.m ., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow and/or Jamie Plisner of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Ms. Plisner at (212) 885-5298 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Thank you.
Very truly yours,
CADRENAL THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm December 30, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Cadrenal Therapeutics, Inc. Registration Statement on Form S-1 Filed December 29, 2025 File No: 333-292444 Dear Mr. Buchmiller: Cadrenal Therapeutics, Inc. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-292444), be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Wednesday, December 31, 2025 , at 4:00 p.m ., Eastern Time, or as soon as reasonably practicable thereafter. The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. The Registrant hereby authorizes Leslie Marlow and/or Jamie Plisner of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Ms. Plisner at (212) 885-5298 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted. Thank you. Very truly yours, CADRENAL THERAPEUTICS, INC. By: /s/ Quang X. Pham Name: Quang X. Pham Title: Chief Executive Officer cc: Leslie Marlow, Blank Rome LLP Jamie Plisner, Blank Rome LLP